Revolution Medicines (RVMD) Non-Current Deferred Tax Liability (2018 - 2025)
Historic Non-Current Deferred Tax Liability for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to $2.4 million.
- Revolution Medicines' Non-Current Deferred Tax Liability fell 2446.23% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 2446.23%. This contributed to the annual value of $2.4 million for FY2024, which is 2446.23% down from last year.
- As of Q3 2025, Revolution Medicines' Non-Current Deferred Tax Liability stood at $2.4 million, which was down 2446.23% from $2.4 million recorded in Q2 2025.
- Revolution Medicines' Non-Current Deferred Tax Liability's 5-year high stood at $7.4 million during Q1 2021, with a 5-year trough of $2.4 million in Q4 2024.
- Its 5-year average for Non-Current Deferred Tax Liability is $5.2 million, with a median of $7.0 million in 2022.
- In the last 5 years, Revolution Medicines' Non-Current Deferred Tax Liability surged by 506.7% in 2021 and then plummeted by 5581.98% in 2023.
- Quarter analysis of 5 years shows Revolution Medicines' Non-Current Deferred Tax Liability stood at $7.4 million in 2021, then dropped by 5.63% to $7.0 million in 2022, then plummeted by 55.66% to $3.1 million in 2023, then decreased by 24.46% to $2.4 million in 2024, then changed by 0.0% to $2.4 million in 2025.
- Its Non-Current Deferred Tax Liability stands at $2.4 million for Q3 2025, versus $2.4 million for Q2 2025 and $2.4 million for Q1 2025.